Physician profile
Patrick Michael Gray
NPI 1427040088
$14,701.14
in general payments reported to CMS, 2019-2025
60 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,360 · 2020: $1,788 · 2021: $2,390 · 2022: $2,389 · 2023: $2,132 · 2024: $2,160 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,773.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,559.95 | 2019-2025 | |
| Novo Nordisk INC | $1,468.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,119.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $767.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $738.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $667.57 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $589.30 | 2019-2024 | Xarelto |
| Amgen INC. | $573.22 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Boston Scientific Corporation | $563.53 | 2019-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $549.26 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $472.77 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $469.75 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $426.36 | 2019-2025 | Verquvo, Belsomra |
| Daiichi Sankyo INC. | $346.48 | 2020-2023 | Injectafer |
| Astellas Pharma US INC | $263.65 | 2019-2024 | Myrbetriq, Veozah |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.